A clinical trial of the beta blocker propranolol in premature ejaculation.

A. J. Cooper,R. V. Magnus

DOI: https://doi.org/10.1016/0022-3999(84)90055-2

IF: 4.62

Journal of Psychosomatic Research

Abstract:

What problem does this paper attempt to address?

Study on the Efficacy of Electric Acupuncture in the Treatment of Premature Ejaculation Based on Testosterone Level

Xiangpeng Lu,Hao Han,Zhibiao Zhang,Hao Chen,Xingru Huang,Rui Zhang

DOI: https://doi.org/10.1155/2022/8331688

2022-03-22

Journal of Healthcare Engineering

Abstract:Objective. To investigate the clinical efficacy and possible mechanism of electroacupuncture in the treatment of premature ejaculation. Methods. 50 cases of premature ejaculation patients who met the diagnostic criteria were randomly divided into 2 groups with 25 cases in each group. The observation group was treated with electroacupuncture, and the control group was treated with Longdan Xiegan decoction. The treatment period was 4 weeks. Ejaculation latency (IELT), sexual satisfaction score of patients, sexual satisfaction score of partners, testosterone test, and drug safety assessment were performed in all 4 groups before and after treatment. Results. IELT was prolonged in all groups after treatment, the difference was statistically significant ( P < 0.05 ). At the same time, the IELT of the observation group was significantly higher than that of the control group after treatment. Life satisfaction scores of patients and spouses in 2 groups were improved after treatment compared with before treatment, the difference was statistically significant ( P < 0.05 ). After treatment, the satisfaction scores of patients and spouses in the observation group were higher than those in the control group, and the difference was statistically significant ( P < 0.05 ). Before treatment, there was no significant difference in serum testosterone levels among all groups ( P > 0.05 ). Serum testosterone levels in all groups were decreased after treatment compared with before treatment, with statistical significance ( P < 0.05 ). After treatment, the serum testosterone level of the observation group was lower than that of the control group, and the difference was statistically significant ( P < 0.05 ). During the treatment, the adverse reactions in each group disappeared after treatment, and no obvious abnormality was observed in the safety indicators. Conclusion. Electroacupuncture can improve the symptoms of premature ejaculation, which may be related to the regulation of serum testosterone by acupuncture.

health care sciences & services
The Efficacy of Fluoxetine in the Treatment of Premature Ejaculation

潘寿华,谢立平

DOI: https://doi.org/10.3969/j.issn.1001-1420.2004.07.007

2004-01-01

Journal of Clinical Urology

Abstract:Objective:To evaculate the efficacy of fluoxetine in the treatment of premature ejaculation and after discontinuing the drug whether premature ejaculation will reappear.Method:68 cases of premature ejaculation were divided randomly into three groups(A. B. C). Group A received 20 mg fluoxetine daily for sixteen weeks. Group B received 20 mg fluoxetine daily for twelve weeks, Then received placebo for four weeks . Group C(control group) received placebo for sixteen weeks. The patients were evaluated during visits before and after treatment for intravaginal latencies.Result:The intravaginal latency in three groups were not significantly different at the beginning of treatment (P 0.05 ), After treatment intravaginal latencies increased in Group A and B campared to those before treament and the group C(P 0.01 ), But in B group the patients received placebo after twelve weeks, The intravaginal latency from the fourteenth's week to the sixteenth's week were not significantly different at the beginning of treatment and the control group(P 0.05 ).Conclusion:Fluoxetine is effective treatment for premature ejaculation, But the efficacy can not continue after discontinuing the drug.Fluoxetine is effective treatment for premature ejaculation, But the efficacy can not continue after discontinuing the drug.
Selective penile dorsal nerve neurotomy for patients with premature ejaculation

陈刚,杨克冰,吕伯东,黄晓军,马寅锋,朱铮

2014-01-01

Abstract:Objective To evaluate the efficacy and safety of selective penile dorsal nerve neurotomy in treatment of pre-mature ejaculation. Methods Two hundred and forty patients with premature ejaculation admitted from January 2009 to Jan-uary 2013 were randomly assigned to two groups: 120 patients were treated with selective penile dorsal nerve neurotomy, in addition to oral sertraline hydrochloride (observation group) and 120 patients were treated with oral sertraline hydrochloride tablets only (control group). Intravaginal ejaculation latency time (IELT) and Chinese index of sexual function for premature ejac-ulation- 5(CIPE- 5) of all cases were recorded before and after the treatment. Results IELE in observation group was increased from(0.98±0.32) min before treatment to(6.15±0.26) min after treatment and CIPE- 5 scores were increased from (9.33±2.59) to (21.26±2.66), both indexes were better than those in control group (P<0.05). The overal effective rate of observation group was higher than that of control group(85.0%vs 75.8%, P<0.05). There were no severe complications in two groups. Conclusion Selective penile dorsal nerve neurotomy is a safe, effective and feasible treatment for patients with premature ejaculation.
The clinical control study of fluoxetine for patients with premature ejaculation

liu benchun,xu ke,tong shijun,xu gang,ding qiang,zhang yuanfang

DOI: https://doi.org/10.3969/j.issn.1007-9572.2003.10.010

2003-01-01

Abstract:Objective To demonstrate the effects of fluoxetine for patients with premature ejaculation.Methods Forty-three patients who presented our clinic with premature ejaculation met the study criteria,were divided randomly into 2 groups.Twenty-one cases of Group A received behavior therapeutics for 4 weeks.Group B were treated by 25 mg fluoxetine daily and behavior therapeutics at same time.The patients were evaluated during visits before and 6 weeks later by SCL-90 questionnaire.Results After treatment,There were significant differences between the two groups(P<0.05).But there were no differences in the rate of efficiency and sex satisfaction between the two groups(P>0.05).Conclusion These findings suggest fluoxetine is effective treatment for premature ejaculation,and its effects will be higher when combined with behavior therapeutics.
Clinical Comparative Study of Lcariin Complex Versus Lidocaine for Treatment of Primary Premature Ejaculation

ZHANG Shi-geng,LV Bo-dong,CHEN Shi-tao,HUANG Xiao-jun

DOI: https://doi.org/10.13193/j.archtcm.2012.04.57.zhangshg.090

2012-01-01

Abstract:Objective:To compare the efficacy of Icariin Complex with lidocaine.Methods:Divide the primary premature ejaculation suffers into two groups like the therapy group(Icariin group)and the control group(lidocaine gelgroup)at random,and each group had 48,and 42 suffers in each group respectively had finished the experiment until the deadline of the experiment.Spread proper Icariin(in therapy group)and lidocaine(in the control group)respectively(the medicine quantity depends on the size of the penis)on the skin and the head of the penis in each night,and the course of treatment was 4 weeks.Compare the differences of IELT,CIPE-5 grade,sexual life satisfaction degree,and the changes of penis IIEF-5 before and after the treatment.Results:①At the end of a 4-week treatment,the treatment group IELT value improve from(1.05±0.42)to(5.45±1.25),and the control group IELT value from(10.4±0.58)increased to(32.4±1.18),both groups can significantly improve the IELT,but the treatment group was better than control group(P 0.05).②In therapy group,CIPE-5 from(11.2 ± 2.4)increased to(24.4±2.1),the control group after treatment,CIPE-5 from(12.1±1.8)improved to(19.7±3.2),both groups can significantly improve the rate,but the therapy group wass superior to the control group(P 0.05).③In the treatment group after treatment,satisfactory sexual satisfaction was 61.90%,basic satisfaction was 26.19%,total satisfaction was 88.09%;in the control group after treatment,satisfactory sexual satisfaction was 47.62%,basic satisfaction was 19.05%,total satisfaction was 66.67%,the treatment group was better than control group(P 0.01).④In therapy group,IIEF-5 from(1.05±0.42)improved to(5.45±1.25);in the control group after treatment,IIEF-5 from(1.04±0.58)improved to(3.24±1.18);the treatment group was better than control group(P 0.05).⑤42 cases in the control group and 42 patients in the treatment group were no exception.There were 3 cases with bad reactions pleasure during intercourse,1 case with local erythema,after discontinuation,all discomfort disappeared,adverse reaction rate of treatment group was 9.52%,there was no obvious discomfort in therapy group.Conclusion:The effect of Icariin Complex is satisfactory on the primary premature ejaculation and it has higher advantage of convenient-using and high-security.It can improve erectile function of patients.
Use of seclusion in an English high security hospital

H. Pannu,S. Milne

DOI: https://doi.org/10.1258/rsmmsl.48.4.288

2008-10-01

Abstract:There is a paucity of information about the use of seclusion in secure settings. The aim of this paper was to establish if any significant trends could be found for its use in a high secure setting. A retrospective descriptive survey of seclusions occurring over a one-year period at Rampton Hospital was utilised. Of the 443 patients within the study sample, 131 (29.6%) were involved in episodes of seclusion. Forty-five per cent of women experienced episodes of seclusion as opposed to 27% of men (p=0.004). Women were secluded at an average of 11.4 times, mostly following threatening behaviour, whereas males were secluded at an average of 4.3 times (p=0.03). There were two peak times for initiation of seclusion — 10.00 hrs and 17.00 hrs. The survey concluded that women were nearly twice as likely to be secluded as men and averaged three times as many episodes of seclusion. Younger patients were more likely to experience seclusion and spent longer periods of time in seclusion. No statistically significant differences were found between the use of seclusion and ethnicity. The observations related to female patients were particularly interesting and further studies on seclusion are required to inform upon strategies to minimise its use, with specific attention to female patients.
[Efficacy and safety of dapoxetine in the treatment of premature ejaculation]

Xiao-yu Chen,Ying-wei Qu,Suo-gang Wang

Abstract:Objective: To evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE). Methods: We randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients. Results: Compared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05). Conclusion: Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions.
[Clinical Efficacy of Viagra with Behavior Therapy Against Premature Ejaculation].

Wenhao Tang,Lulin Ma,Lianming Zhao,Yuqing Liu,Zhenwen Chen

DOI: https://doi.org/10.3969/j.issn.1009-3591.2004.05.013

2004-01-01

Abstract:OBJECTIVE:To study the efficacy of Viagra combined with behavior therapy against premature ejaculation (PE).METHODS:Sixty PE patients were divided into two groups randomly: control group (behavior therapy alone) and the group of Viagra combined with behavior therapy. Intra-vaginal ejaculation latency time (IELT) and the coitus satisfaction of the patient and the partner were recorded before and after treatment.RESULTS:The IELTs of the two groups were 0.80 +/- 0.20 and 0.73 +/- 0.24 minutes respectively before treatment, and 1.82 +/- 0.54 and 3.63 +/- 0.55 minutes respectively after treatment. As for IELT and satisfaction degree, Viagra produced better result than behavior therapy.CONCLUSION:During this clinical trial, Viagra combined with behavior therapy prolonged IELT, which suggests that Viagra may be helpful for the treatment of premature ejaculation.
Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology

M D Waldinger

DOI: https://doi.org/10.1038/sj.ijir.3901023

2003-10-01

International Journal of Impotence Research

Abstract:In the last decade, an increasing number of drug studies on premature ejaculation have been published. The methodology used in these studies differed widely. In this review, it is therefore questioned as to how far the differences in methodology could have influenced clinical outcomes. The aim of the present review was to compare the different methodologies that were used in drug studies on premature ejaculation. The majority of these studies were conducted between 1973 and 2003 and were strikingly different in study design and in the quantification of clinical outcomes. It appeared that in some of these studies, placebo and active drug effects were neglected due to an erroneous methodology. The few studies that were using stopwatch assessment at each intercourse at baseline and during treatment and in which the intravaginal ejaculation latency time (IELT) was included appeared to be comparable in their results. The use of a well-defined definition of premature ejaculation, for example, an IELT of less than 1 min revealed reproducible results. Finally, the retrospective use of a questionnaire or a subjective report on ejaculation time induced higher effects with regard to placebo effects and an underestimation of active drug effects. In conclusion, for drug treatment research of premature ejaculation it is recommended to use a randomized double-blind prospective design, the use of the IELT, the use of a stopwatch at each coitus both during a baseline period and during drug treatment and a definition of premature ejaculation as an ejaculation that occurs within 1 min after vaginal penetration.

urology & nephrology
Tadalafil and Fluoxetine in Premature Ejaculation: Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Rogerio M. Mattos,Antonio Marmo Lucon,Miguel Srougi

DOI: https://doi.org/10.1159/000112607

2008-01-01

Urologia Internationalis

Abstract:INTRODUCTION: Premature ejaculation (PE) is a common male sexual disorder. An ideal, reliable and effective treatment is desired by many men and couples affected by this condition.AIM: Evaluate if the association of a phosphodiesterase-5 inhibitor, tadalafil, and a selective serotonin reuptake inhibitor, fluoxetine, can prolong the intravaginal ejaculatory latency time (IELT) in men with lifelong premature ejaculation.METHODS: Sixty patients with lifelong premature ejaculation and without erectile dysfunction (ED) with IELT less than 90 s were enrolled in the protocol and randomized into 4 groups to use a combination of medications: (1) tadalafil 20 mg plus fluoxetine 90 mg, (2) fluoxetine 90 mg plus placebo, (3) tadalafil 20 mg plus placebo, and (4) two different placebo capsules (control). Before starting the medications, each man timed his IELT with a stopwatch, and likewise during the treatment period. Fluoxetine 90 mg or placebo was taken once a week plus tadalafil 20 mg or placebo within a 36-hour frame of intended sexual intercourse with a steady partner. Patients were prospectively followed for 12 weeks. One-way ANOVA was used for statistical comparisons of IELT results in each group.RESULTS: Mean IELT before starting treatment was 51.3 +/- 23 s. With one-way ANOVA, a statistically significant difference in post-treatment IELT was seen with combination treatment compared to placebo (p < 0.001). There were increases in IELT from baseline in patients using fluoxetine plus tadalafil (49.57 +/- 25.87 to 336.13 +/- 224.77) (p < 0.001), fluoxetine (56.55 +/- 18.55 to 233.62 +/- 105.08) (p < 0.001) and tadalafil (49.26 +/- 19.43 to 186.53 +/- 159.05) (p = 0.001). The increases in each group were statistically significant compared to the placebo (49.86 +/- 19.43 to 67.82 +/- 46.18) (p = 0.042).CONCLUSION: Fluoxetine plus tadalafil significantly increased the IELT from baseline in men with lifelong premature ejaculation when compared to placebo, tadalafil or fluoxetine.

urology & nephrology
Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study

M R Safarinejad,S Y Hosseini

DOI: https://doi.org/10.1038/sj.ijir.3901384

2005-08-18

International Journal of Impotence Research

Abstract:We evaluate the efficacy and safety of citalopram, a potent and highly selective serotonin reuptake inhibitor (SSRI) antidepressant, in patients with premature ejaculation (PE). In total, 58 potent men with PE were included in the study. Patients were randomly assigned to receive 20 mg oral daily citalopram (group 1, n=29) or placebo (group 2, n=29), during a 12-week period for each agent. Pretreatment evaluation included history and physical examination, intravaginal ejaculatory latency time (IVELT) evaluation, International Index of Erectile Function (IIEF) and Meares–Stamey test. The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study and in 3- and 6-month follow-up after cessation of treatment, using responses to IIEF, IVELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. The trial was completed by 51 (88%) men. Analysis revealed a difference in the evolution of IVELT delay over time (P<0.001). The IVELT after citalopram and placebo gradually increased from 32 and 28 s to approximately 268 and 38 s, respectively. The mean weekly intercourse episodes increased from pretreatment values of 1.3 and 1.2 to 2.4 and 1.4, for citalopram and placebo, respectively (P<0.05). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 16 and 10 at 12-week treatment in groups 1 and 2, respectively (P<0.05). Mean IVELT in group 1 was 210 and 198 s at 3- and 6-month follow-up, while in group 2 it was 27 and 25 s (P<0.001), respectively. At 3- and six-month intercourse satisfaction domain values of IIEF were 15 and 14 in group 1 and 10 and 10 (P<0.05) in group 2, respectively. Group 1 patients reported a significantly higher number of intercourse episodes per week (P<0.05). Mean number of adverse events was 12 for citalopram and 4 for placebo (P<0.05). In conclusion, these results indicate that citalopram has significantly better results in terms of IVELT and intercourse satisfaction versus placebo. Further studies with different dosages and treatment regimens are necessary to draw final conclusions on the efficacy of this drug in PE and to prolong the efficacy.

urology & nephrology
The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study.

Baibing Yang,Zhiwei Hong,Dustin C. Luse,Youfeng Han,Guohai Sun,Yuming Feng,Chenwang Zhang,Chao Sun,Zhipeng Xu,Hai Chen,Bing Yao,Kaifeng Liu,Weidong Zhu,Yun Chen,Run Wang,Yutian Dai,Jiadong Xia

DOI: https://doi.org/10.1097/ju.0000000000002198

IF: 7.6

2021-01-01

The Journal of Urology

Abstract:Purpose: Premature ejaculation (PE) is one of the most common male sexual dysfunctions. Local anesthetics (LAs) and dapoxetine are frequently used to treat PE; however, previous studies show variable efficacy. This study aims to determine the efficacy of LAs and dapoxetine using a novel classification based on neurophysiological tests. Materials and Methods: This multicenter cohort study enrolled adult men (568) with an intravaginal ejaculatory latency time (IELT) <= 2 minutes. Patients were divided into 4 groups according to the results of neurophysiological tests and assigned different treatments for 12 weeks: 1) penile sensory hyperexcitability type (Sens)-LAs; 2) penile sympathetic hyperexcitability type (Symp)-dapoxetine; 3) mixed type (Mixed)-both LAs and dapoxetine; 4) normal type (Norm)-both LAs and dapoxetine. Self-estimated IELT and patient-reported outcomes were recorded. Results: The total percentage of men achieving IELT >2 minutes and >= 5 minutes after treatment were 82.7% and 76.7%, respectively. For men with abnormal results of neurophysiological tests, 401 (86.6%) had improved IELT >2 minutes after the 12-week treatment course, in which 375 (81.0%) achieved IELT >= 5 minutes. All patient-reported outcome measures improved in each group after 12 weeks of treatment, with greater improvements among those with abnormal neurophysiological tests. Conclusions: The efficacy of LAs and dapoxetine increased in PE patients with abnormal results of neurophysiological tests. This novel classification of PE using neurophysiological tests could help guide and improve efficacy of PE therapies.
Treatment of primary premature ejaculation with sertraline hydrochloride

Zhanju He,Jie Jin,Kai Zhang

DOI: https://doi.org/10.3969/j.issn.1008-0848.2008.09.012

2008-01-01

Abstract:Objective: To investigate the possibility of self-therapy for the treatment of primary premature ejaculation, we compared the efficacy of sertraline taken as needed with that of continuous medication. Methods: This was an open-label study. Efficacy included (a)intravaginal ejaculation latency time and(b) patient and partner satisfaction. Results: Among the 81, the mean ejaculation latency was (0.08±0.5)minutes before treatment (6.5±4.3) minutes after 2 weeks of 50 mg daily, (5.7±2.8)minutes after 2 weeks of 50 or 100 mg PRN, and (4.1±1.6) minutes after 4 weeks of 50 or 100 mg PRN. Mean sexual satisfaction scores for men were (0.47±0.8) before treatment, (3.8±1.4)after 2 weeks of 50 mg daily, (3.2±1.3)after 2 weeks of 50 or 100 mg PRN, and 3.0±1.8 after 4 weeks of 50 or 100 mg PRN. For their partners, mean sexual satisfaction scores were (0.38±0.21) before treatment, (3.3±1.6) after 2 weeks of 50 mg daily, (3.0±1.7)after 2 weeks of 50 or 100 mg PRN, and (2.9±1.4) after 4 weeks of 50 or 100 mg PRN. Conclusion: If our results are supported by additional long-term clinical studies, self-therapy with sertraline taken PRN for the treatment of primary premature ejaculation may offer an attractive option.
Effect evaluation of Paroxetine and Sertraline in the treatment of premature ejaculation

Weixing Zhang,Junchang Qin,Rui Wang,Lei Wang,Jie Zhang

DOI: https://doi.org/10.3969/j.issn.1008-0848.2012.02.011

2012-01-01

Abstract:Objectives To evaluate the effect and safety of Paroxetine and Sertraline in the treatment of patients with premature ejaculation. Methods A total of 190 patients were enrolled in this randomized trial. They all met the criterion of the Premature Ejaculation Diagnosis Tool. They were divided randomly into Group A (treated with the pause-squeeze technique),Group B (treated with 20mg/d Fluoxetine), Group C (treated with 30mg/d Fluoxeting), Group D(treated with 50mg/d Sertraline) and Group E (treated with 100mg/d Sertraline). Before treatment, 6 weeks and 12 weeks after treatment, the patients had to report about the intravaginal ejaculatory latency time (IELT), sexual satisfaction, and adverse reaction. Results One hundred and four participants completed this study. After 6 weeks' treatment, IELT was prolonged significantly compared with that before treatment(P<0.05). It prolonged much in Group C compared with that in Group A (t=3.92, P<0.01); After 12 weeks, it was much longer in patients treated with Paroxetine and Sertraline than that in patients treated with the pause-squeeze technique. The ratio of sexual satisfaction was increased significantly in Group C, which exceeded 60%. The common adverse reaction in a long period of treatment with Paroxetine and Sertraline was drowsiness, headache, insomnia and diarrhea, but no significant difference was found among the groups in terms of the adverse reaction ratio (x2=2.90, P>0.05). Conclusion Paroxetine and Sertraline are able to manage premature ejaculation through prolonging IELT and improving sexual satisfaction, Moreover, they can be well tolerated, and especially Paroxetine is superior to Sertraline.
Correlation between serum tryptophan metabolism and treatment efficacy of dapoxetine in patients with premature ejaculation: A pilot study

Chenglun Wu,Shengyu Huang,Zhuojie Liu,Yixin Wang,Yuanqiang Zhu,Zhi‐Jun Zang

DOI: https://doi.org/10.1111/andr.13632

2024-03-23

Andrology

Abstract:Introduction Primary premature ejaculation (PPE) is a common male neurobiological disorder. Currently, there is consensus that the impairment in central serotonin (5‐HT) neurotransmission constitutes a key pathogenic factor in PPE. Selective serotonin reuptake inhibitors (SSRIs) serve as the primary pharmacological intervention; however, a comprehensive elucidation of their mechanism of action remains incomplete. Owing to significant individual variability in efficacy, SSRIs exhibit a high discontinuation rate. Hence, there is an urgent need to address the selection of SSRIs for PPE treatment. Objective This study aims to investigate the characteristics of tryptophan (TRP) metabolism in patients with PPE and to assess its influence on the efficacy of SSRIs. Methods The exploratory study included a total of 16 patients with PPE and 16 control subjects who were healthy men without any sexual dysfunction. Upon enrollment in the study, all participants underwent a thorough medical history review and physical examination. Subsequently, their serum levels of TRP, its metabolites, large neutral amino acids (LNAAs), and metabolite ratios were assessed using a liquid chromatography–mass spectrometry (LC–MS) assay. After a period of 4 weeks of dapoxetine treatment, all patients with PPE underwent reassessment using the Premature Ejaculation Diagnostic Tool (PEDT) score and intravaginal ejaculatory latency time (IELT) test. Results The ratio of serum TRP to other LNAAs (TRP/LNAAs) in patients with PPE was found to be significantly lower compared to the control group (P

andrology
AB013. Diagnosis and Treatment of Premature Ejaculation

Bing Gao,Zhichao Zhang,Yiming Yuan,Jing Peng,Zhongcheng Xin,Yinglu Guo

DOI: https://doi.org/10.21037/tau.2017.s013

2017-01-01

Translational Andrology and Urology

Abstract:: The definition of premature ejaculation has not yet been agreed upon in the international community, which can be divided into primary premature ejaculation, secondary premature ejaculation, variability premature ejaculation and premature ejaculation likely erectile dysfunction. The diagnosis can be carried out based on the patient’s medical history, the sexual evaluation table and the neurological examination of the premature ejaculation in China, Neurologic examination including the sensory evoked potentials of the penile dorsal nerve (DNSEP) and the sensory evoked potentials of the penis glans (GPSEP). Treatment methods can choose psychological counseling, behavioral therapy, drug therapy and surgical treatment. Drug therapy including topical drugs, serotonin reuptake inhibitors (SSRi), receptor blockers, type 5 phosphodiesterase inhibitors (PDE5i), etc., of the latest medications can choose hydrochloric acid of dapoxetine (Priligy) treatment.
Clinical Study of Ss-Cream in Patients with Lifelong Premature Ejaculation

HK Choi,GW Jung,KH Moon,ZC Xin,YD Choi,WH Lee,KH Rha,YJ Choi,DK Kim

DOI: https://doi.org/10.1016/s0090-4295(99)00415-x

IF: 2.633

2000-01-01

Urology

Abstract:Objectives. To investigate the clinical efficacy of SS-cream, the topical agent made from the extracts of nine natural products for the treatment of premature ejaculation, we performed a double-blind, randomized, placebo-controlled Phase III clinical study of patients with lifelong premature ejaculation in three medical centers.Methods. One hundred six patients (mean age 38.7 +/- 0.61 years) completed this study, The ejaculatory latency measured by stopwatch and sexual satisfaction ratio of both partner and patient were investigated twice in the screening period and once after each treatment (1 placebo 0.20 g and 5 SS-cream 0.20 g for a total of six treatments). Patients were instructed to apply the cream on the glans penis 1 hour before sexual intercourse in a double-blind randomized fashion. Clinical efficacy was compared with the prolongation of ejaculatory latency and improvement of the sexual satisfaction ratio before and after each treatment.Results. in the screening period, the mean ejaculatory latency was assessed at 1.37 +/- 0.12 minutes, and neither the patients nor their partners were satisfied with their sexual lives. After treatment, the mean ejaculatory latency was prolonged to 2.45 +/- 0.29 minutes in the placebo group and 10.92 +/- 0.95 minutes in the SS-cream group. The clinical efficacy of placebo and SS-cream as judged by an ejaculatory latency time prolonged more than 2 minutes was 15.09% and 79.81%, respectively. The improvement of sexual satisfaction to a grade higher than effective was 19.81% and 82.19%, respectively, for placebo and SS-cream. Of 530 trials of SS-cream, 98 (18.49%) resulted in a sense of mild local burning and mild pain. No adverse effect on sexual function or partner and no systemic side effects were observed.Conclusions. According to these results, SS-cream is effective and safe in the treatment of premature ejaculation, with mild local side effects. (C) 2000, Elsevier Science Inc.
Expression of basement membrane zone antigens at the dermo-epibolic junction in organ cultures of human skin.

Helmut Hintner,Peter O. Fritsch,J. Foidart,G. Stingl,Gerold Schuler,Stephen I. Katz

DOI: https://doi.org/10.1111/1523-1747.EP12541715

IF: 7.59

1980-04-01

Journal of Investigative Dermatology

Abstract:Using the epithelial outgrowth in organ cultures of human skin ("epiboly") as a model system for basement membrane zone neogenesis, the emergence of various antigenic determinants of the junction zone (bullous pemphigoid antigen, type IV collagen and laminin) was studied and the time sequence of their appearance assessed. All 3 antigens were found at the newly built dermo-epibolic junction; their synthesis, however, followed a distinct time sequence: bullous pemphigoid antigens emerged synchronously with the advancing tip of the migrating epithelium, whereas type IV collagen and to a greater extent, laminin, appeared with considerable delay. At the ultrastructural level, the formation of basal lamina accompanied the emergence of type IV collagen and laminin.
Clinicopathological study of nondiabetic renal disease in type 2 diabetic patients: A single center experience from India.

K. Kanodia,A. Vanikar,L. Nigam,Rashmi D. Patel,K. Suthar,H. Patel

DOI: https://doi.org/10.4103/1319-2442.220877

2017-11-01

Saudi Journal of Kidney Diseases and Transplantation

Abstract:Diabetic nephropathy (DN) is a major complication of diabetes mellitus (DM), leading to chronic kidney disease/end-stage renal disease. Wide spectrum of nondiabetic renal diseases (NDRD) is reported in type-2 diabetes (type-2 DM). We carried out this single-center study to find clinical, laboratory, and histological features of NDRD in type-2 DM patients and to assess the prevalence of NDRD in India. A single-center retrospective study which included analysis of renal biopsies from patients with type-2 DM, performed between January 2008 and September 2016. Biopsy findings were categorized into three groups, Group-I (isolated NDRD); Group-II (NDRD superimposed on underlying DN); and Group-III (isolated DN). Out of 152 diabetic patients (111 males and 41 females), 35 (23.03%) patients were of Group-I (isolated NDRD), 35 (23.03%) of Group-II (NDRD superimposed on underlying DN), and 82 (53.95%) of Group-III (isolated DN). The mean age (in years) was 55.08 ± 10.71, 55.65 ± 8.71, and 54.45 ± 9.01 respectively in Group-I, II, and III. Nephrotic syndrome (NS) was the most common clinical presentation in all groups. Duration of DM was significantly shorter in Group-I than in Group-II. Diabetic retinopathy was absent in Group-I. Proteinuria was more in Group-III than Group-I. Low serum C3 and/or C4 levels was observed in five (14.29%) cases of Group-I and Group-II each and two (2.43%) cases of Group-III. Nearly, 70 (46.05%) patients were found to have NDRD either in isolated form or as combined lesions. The most common histological types of NDRD were acute tubulointerstitial nephritis (38.57%) followed by benign nephrosclerosis (15.72%), membranous nephropathy (10%), IgA nephropathy (7.14%), and membranoproliferative glomerulonephritis (7.14%). The incidence of NDRD (with/without DN) in type-2 DM is very high. Shorter duration of diabetes, hematuria, absence of retinopathy, low serum complement levels, and nephrotic range proteinuria are predictors of NDRD.

A clinical trial of the beta blocker propranolol in premature ejaculation.

Study on the Efficacy of Electric Acupuncture in the Treatment of Premature Ejaculation Based on Testosterone Level

The Efficacy of Fluoxetine in the Treatment of Premature Ejaculation

Selective penile dorsal nerve neurotomy for patients with premature ejaculation

The clinical control study of fluoxetine for patients with premature ejaculation

Clinical Comparative Study of Lcariin Complex Versus Lidocaine for Treatment of Primary Premature Ejaculation

Use of seclusion in an English high security hospital

[Efficacy and safety of dapoxetine in the treatment of premature ejaculation]

[Clinical Efficacy of Viagra with Behavior Therapy Against Premature Ejaculation].

Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology

Tadalafil and Fluoxetine in Premature Ejaculation: Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study

The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study.

Treatment of primary premature ejaculation with sertraline hydrochloride

Effect evaluation of Paroxetine and Sertraline in the treatment of premature ejaculation

Correlation between serum tryptophan metabolism and treatment efficacy of dapoxetine in patients with premature ejaculation: A pilot study

AB013. Diagnosis and Treatment of Premature Ejaculation

Clinical Study of Ss-Cream in Patients with Lifelong Premature Ejaculation

Expression of basement membrane zone antigens at the dermo-epibolic junction in organ cultures of human skin.

Clinicopathological study of nondiabetic renal disease in type 2 diabetic patients: A single center experience from India.